Methods of determining whether a subject suffering from lupus nephritis (ln) will achieve a response with an induction therapy

Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Now the inventors analyzed the phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy volunteers. The inventors found that MAIT cell frequencies are markedly reduced in blood of LN patients. More particularly, among LN patients, baseline MAIT cell frequency, Ki-67 expression evaluating proliferative activity and granzyme B production measuring cytotoxicity represent promising prognostic factors of renal response one year after induction therapy. In conclusion, the inventors showed that baseline frequency and cytotoxic profile of MAIT cells may represent a promising prognostic factor of renal remission one year after induction therapy.

Keywords: Lupus Nephritis, Systemic lupus erythematosus, MAIT Cells, Flow Cytometry, Diagnosis, Treatment response prediction
Patent Application number: EP23 306 270.2 on 24/07/23 and PCT/EP2024/070803
Inventors:
FLAMENT Héloïse; MONTEIRO Renato; LEHUEN-MONTEIRO Agnès
Publications:
Front Immunol, 2023 Oct 10:14:1205405, Litvinova et al., MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome, . doi: 10.3389/fimmu.2023.1205405. eCollection 2023.

Reference:

BIO23304-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 2023-07-24

You might also be interested in